DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20184454

Study of prevalence of metabolic syndrome in androgenetic alopecia

M. Mahitha Devi, P. V. Krishnam Raju, K. V. T. Gopal, T. Narayana Rao

Abstract


Background: Androgenetic alopecia (AGA) is commonly known as male pattern baldness has a prevalence of up to 50% in men worldwide. It occurs in most patients before the age of 40 years. It is characterized by a progressive conversion of terminal hair into miniaturized hair defined by various patterns. Various studies have shown that androgenetic alopecia have significant physical and psychological morbidity and a lowered dermatological life quality index.

Methods: The study included 75 patients with clinical diagnosis of AGA and 75 age and sex matched controls. After taking complete history, general examination and thorough dermatological examination was performed in all cases to grade the severity of AGA. Fasting serum samples were taken from all cases and controls and assayed for fasting plasma glucose and lipid profile. Metabolic syndrome (MS) was diagnosed according to 2005 revised National Cholesterol Education Programme’s Adult Treatment Panel III (NCEP ATP III). Chi square test was used for statistical analysis.

Results: Metabolic syndrome was seen in 25 cases (33.3%) compared to 11 controls (14%), which was statistically significant (p=0.007). Statistically significant increased prevalence of raised TGL levels (p=0.002), raised LDL levels (p=0.024), low HDL levels (p=0.0001), diabetes mellitus (p=0.004) was also observed in AGA.

Conclusions: There is a clear association between AGA and MS and there is statistically significant prevalence of MS in patients with increasing severity and duration of AGA. Screening is required for early detection of dyslipidemia, diabetes mellitus and MS in all patients of AGA to prevent long-term morbidity.


Keywords


AGA, Dyslipidemia, Diabetes mellitus, Metabolic syndrome

Full Text:

PDF

References


Messenger AG, Sinclair RD, David PF, de Berker AR. Acquired hair disorders of hair. In : Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. Oxford: Wiley-Blackwell; 2016: 89.14–89.24.

Otberg N, Shapiro J. Hair growth disorders. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s Dermatology in general medicine. 8th ed. New York: McGraw Hill; 2012: 979–1008.

Dhurat R, Sukesh MS. Hair and scalp disorders. In Sacchindanand S, Oberai C, Inamdar AC, editors. IADVL Text book of Dermatology. 4th ed. Mumbai: Bhalani Publishing House; 2015: 1468-1587.

Hamilton, JB. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat. 1942;71:451-80.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.

Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía-Eisman A, Girón-Prieto MS, Naranjo-Sintes R. A comparative study of dyslipidaemia in men and woman with androgenic alopecia. Acta Derm Venereol. 2010;90:485-7.

Banger H, Malhotra SK, Singh S, Mahajan M. Is Early Onset Androgenic Alopecia a Marker of Metabolic Syndrome and Carotid Artery Atherosclerosis in Young Indian Male Patients? Int J Trichol. 2015:141-7.

Chakrabarty S, Hariharan R, Gowda DG, Suresh H. Association of premature androgenetic alopecia and metabolic syndrome in a young Indian population. Int J Trichol. 2014;6:50-3.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: Pathogenesis and potential for therapy. Expert Rev Mol Med. 2004;4:1-11.

Birch MP, Lashen H, Agarwal S, Messenger AG. Female pattern hair loss, sebum excretion and the end-organ response to androgens. Br J Dermatol. 2006;154(1):85-9.

Otberg N, Finner AM, Shapiro J. androgenetic alopecia. Endocrinol Metab Clin North Am. 2007;36:379-98.

Fujimoto R, Morimoto I, Morita E, Sugimoto H, Ito Y, Eto S. Androgen receptors, 5alfa-reductase activity and androgen- dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol. 1994;50:169-74.

Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction; a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8.

Acibucu F., Kayatas M., Candan F. The association of insulin resistance and metabolic syndrome in early androgenetic alopecia. Singapore Med J. 2010;51(12):931–6.

Bakry OA, Shoeib MAM, Shafiee ME, Hassan A. androgeneticalopecia, metabolicsyndrome, and insulin resistance: is there any association? A case control study. Indian Dermatol Online J. 2014;5:276-81.

Gopinath H, Upadya GM. Metabolic syndrome in androgenic alopecia. Indian Dermatol Venereal Leprol. 2016;82:404-8.

Sue LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: A community based survey. Br J Dermatol. 2010;163;371-7.

Pengsalae N, Tanglertsampan C, Phichawong T, Lee S. Association of early-onset androgenetic alopecia and metabolic syndrome in Thai men: A case-control study. J Med Assoc Thai. 2013;96:947-51.

Yi SM, Son SW, Lee KG, Kim SH, Lee SK, Cho ER, et al. Gender-specific association of androgenetic alopecia with metabolic syndrome in a middle-aged Korean population. Br J Dermatol. 2012;167:306-3.

Gok SO, Belli AA, Dervis E. Is there really relationship between androgenetic alopecia and metabolic syndrome. Dermat Res Pract. 2015;2015:980310.

Sharma L, Dubey A, Gupta PR, Agrawal A. Angrogenetic alopecia and risk of coronary artery disease. Indian Dermatol Online J. 2013;4(4):283-7.